Table of Contents
1. Chapter one - Introduction
- 1.1. KEY TAKE AWAYS
- 1.2. Report description
- 1.3. Markets Covered
- 1.4. STAKEHOLDERS
2. Chapter Two - Summary
3. Chapter Three - Market Overview
- 3.1. Evolution for Autoimmune treatments
- 3.2. FOCUS AREAS for the DEVELOPMENT autoimmune treatment
- 3.3. Defining the overall autoimmune treatment market
- 3.4. Defining the Autoimmune treatment market by geography
4. Chapter four - global autoimmune treatment market by application
- 4.1. Systemic Autoimmune Diseases
- 4.2. Rheumatoid Arthritis (RA)
- 4.2.1. Drivers
- 4.2.1.1. Large number of people suffer from RA
- 4.2.1.2. RA requires continuous treatment as it is a chronic disease
- 4.2.1.3. Large middle adulthood population is more prone to RA
- 4.2.2. Restraints
- 4.2.2.1. No fixed treatment is available for RA
- 4.2.2.2. Fewer insurance coverage and reimbursement for RA treatment
- 4.2.3. Global RA Market for Consultation & Diagnosis
- 4.2.4. Global RA market for therapy & monitoring
- 4.2.4.1. Global DMARD and biologic DMARD Therapy in RA
- 4.2.4.2. Global Bridge Therapy market in RA
- 4.2.4.3. Global Other Therapies market in RA
- 4.2.5. Global RA Market for Drugs
- 4.2.5.1. Global NSAID market in RA
- 4.2.5.2. Global Corticosteroids Market in RA
- 4.2.5.3. Global Other Drugs Market in RA
- 4.2.6. Global other products and services market in RA
- 4.2.7. Drug Approvals
- 4.3. Psoriasis
- 4.3.1. Drivers
- 4.3.1.1. Psoriasis starts at early age, gives a long earning period
- 4.3.1.2. Large patient base is driving the market
- 4.3.1.3. Psoriasis is also genetically transferred
- 4.3.2. Market restraints
- 4.3.2.1. Over the counter (OTC) drugs can result into adverse drug
reactions (ADRs)
- 4.3.2.2. No specific diagnosis and treatment hinders the market growth
- 4.3.3. Global Consultation & Diagnosis Market in Psoriasis
- 4.3.4. Global therapy & monitoring market in psoriasis
- 4.3.5. Global Drugs Market in Psoriasis
- 4.3.5.1. Global Anthralin Market in Psoriasis
- 4.3.5.2. Global Calcipotriene Market in Psoriasis
- 4.3.5.3. Global NSAIDs market in Psoriasis
- 4.4. Lupus
- 4.5. Other Systemic Diseases
- 4.6. Localized autoimmune Diseases
- 4.7. Multiple Sclerosis (MS)
- 4.7.1. Drivers
- 4.7.1.1. MS is a chronic disorder which requires lifetime treatment
- 4.7.1.2. Large number of MS patients across the globe
- 4.7.1.3. Increased public awareness is leading to early initiation of
treatment
- 4.7.1.4. Combination of therapies is increasing the growth
opportunities
- 4.7.2. Restraints
- 4.7.2.1. Complicated nature of disease with limited drugs is hindering
the market growth
- 4.7.2.2. Side effects of injectables and high cost of oral drugs is
affecting the growth
- 4.7.3. Global Drugs market in multiple sclerosis
- 4.7.4. Drug Approval
- 4.8. Inflammatory Bowel Disease (IBD)
- 4.8.1. Drivers
- 4.8.1.1. IBD a genetically transferred disease, increases the
incidence of cases
- 4.8.1.2. Early treatment of IBD is driving the market
- 4.8.1.3. Lifelong treatment gives a long earning period
- 4.8.2. Restraints
- 4.8.2.1. Insurance coverage reimbursement problems for IBD patients
- 4.8.3. Global Consultation & Diagnosis Market in IBD
- 4.8.4. Global therapy & monitoring market in IBD
- 4.8.5. Global drugs market in IBD
- 4.9. Type I diabetes
- 4.9.1. Easy insurance coverage for diabetes patients
- 4.9.2. Type I diabetes is still considered to be a chronic disorder
- 4.9.3. Casual behavior towards treatment is restraining the Market growth
- 4.10. Thyroid
- 4.11. Other Localized Autoimmune diseases
5. Chapter five - Global Autoimmune treatment Market By Product
- 5.1. Drugs
- 5.1.1. Non-Steroidal anti-inflammatory drugs (NSAID)
- 5.1.1.1. Drivers
- 5.1.1.2. Restraints
- 5.1.2. GLUCOCORTICOIDS
- 5.1.3. METHOTREXATE
- 5.1.3.1. Drivers & Restraints
- 5.1.4. Hydroxychloroquine (HCQ)
- 5.1.4.1. Drivers
- 5.1.4.2. Restraints
- 5.1.5. Anthralin
- 5.1.6. Calicipotriene
- 5.1.7. Corticosteriods (Steriods)
- 5.1.8. Aminosalicylates/5-ASA/Mesalazine
- 5.1.9. Avonex
- 5.1.10. Rebif
- 5.1.11. Copaxone
- 5.1.11.1. Fewer side effects is increasing the demand
- 5.1.11.2. Reduces relapses in relapsing-remitting multiple sclerosis
(RRMS)
- 5.1.12. Betaseron
- 5.1.13. Comparison of four MS drugs
- 5.1.14. Other Drugs
- 5.2. Diagnostic equipment
- 5.3. Therapeutic and monitoring equipment
- 5.4. Other Products
6. Chapter six - global services market in autoimmune treatment
- 6.1. Consultation & Diagnosis
- 6.2. Therapy and monitoring
- 6.3. Drug Development
- 6.4. Drivers
- 6.4.1. Drugs form the mainstream, most revenue-generating treatment
- 6.4.2. Introduction of biosimilars opens up more opportunities
7. Chapter seven - global Technology market in autoimmune treatment
- 7.1. DMARD AND BIOLOGIC DMARD THERAPY
- 7.1.1. Drivers
- 7.1.1.1. Effective therapies with biologic DMARD and the availability
of multiple drugs
- 7.1.1.2. Cost-effective treatment is boosting the demand for the
therapy
- 7.1.2. Restraints
- 7.2. Bridge Therapy
- 7.3. Topical Therapy
- 7.4. Fecal Bacteriotherapy
- 7.5. Helminthic Therapy
- 7.5.1. Drivers & Restraints
- 7.5.1.1. Higher efficacy
- 7.5.1.2. Expensive treatment hindering the market growth
- 7.6. Hematopoietic stem cell transplantation
- 7.6.1. Drivers & Restraints
- 7.7. Recombinant Technology
8. Chapter Eight - Global Autoimmune Treatment Market by Geography
- 8.1. Autoimmune treatment market in North America
- 8.1.1. North American Autoimmune treatment Market by
- 8.1.2. Application
- 8.2. Autoimmune treatment market in Europe
- 8.2.1. European autoimmune treatment market by application
- 8.3. Autoimmune treatment market in Asia Pacific
- 8.4. Autoimmune treatment market in ROW
9. Chapter Nine - Patent Analysis
- 9.1. Analysis of patents by geography
10. Chapter Ten - Company Profiles
- 10.1. 4SC AG
- 10.2. Abbott Laboratories
- 10.3. Active Biotech
- 10.4. Amgen
- 10.5. Angiotech Pharmaceuticals
- 10.6. Astellas Pharma
- 10.7. AstraZeneca Plc
- 10.8. Autoimmune Inc
- 10.9. Bayer-Schering Pharmaceuticals
- 10.10. BioCryst Pharmaceuticals Inc.
- 10.11. Biogen Idec, Inc.
- 10.12. Boehringer Ingelheim Gmbh
- 10.13. Bristol-Myers Squibb Co.
- 10.14. Centocor, Inc
- 10.15. Cytokine PharmaSciences, Inc
- 10.16. Elan Corporation, plc
- 10.17. Eli Lilly & Co.
- 10.18. Forest Laboratories, Inc.
- 10.19. Galderma Laboratories
- 10.20. Genentech, Inc.
- 10.21. Glaxo SmithKline Plc
- 10.22. Isis Pharmaceuticals, Inc.
- 10.23. Isotechnika, Inc.
- 10.24. Johnson & Johnson
- 10.25. Ligand Pharmaceuticals
- 10.26. Lupin
- 10.27. Merk Serono SA
- 10.28. Mitsubishi Tanabe Pharma Corporation
- 10.29. Novartis
- 10.30. Pfizer
- 10.31. Roche
- 10.32. Sanofi-Aventis
- 10.33. Schering-Plough
- 10.34. Teva
- 10.35. UCB Pharma Inc
- 10.36. Vertex Pharmaceuticals Incorporated
- 10.37. Warner Chilcott
- 10.38. Watson Pharmaceuticals, Inc
- 10.39. Wyeth
- 10.40. ZymoGenetics, Inc.
Appendix
- 1. Table 1
- 2. U.S. patents
- 3. Source: MarketsandMarkets
- 4. Europe Patent List
- 5. Source: MarketsandMarkets
- 6. Table 2
- 7. Japan Patent Table
- 8. Source: MarketsandMarkets
List of Tables
- SUMMARY TABLE GLOBAL MARKET FOR AUTOIMMUNE TREATMENT, BY APPLICATIONS 2007
- 2014 ($ MILLIONS)
- TABLE 1 GLOBAL AUTOIMMUNE TREATMENT MARKET 2007 - 2014 ($ MILLIONS)
- TABLE 2 GLOBAL SYSTEMIC DISEASES MARKET, BY APPLICATIONS 2007 - 2014 ($
MILLIONS)
- TABLE 3 GLOBAL SYSTEMIC DISEASES MARKET, BY GEOGRAPHY 2007 - 2014 ($
MILLIONS)
- TABLE 4 GLOBAL RHEUMATOID ARTHRITIS MARKET, BY APPLICATIONS 2007 - 2014 ($
MILLIONS)
- TABLE 5 GLOBAL RHEUMATOID ARTHRITS APPLICATIONS MARKET, BY GEOGRAPHY 2007
- 2014 ($ MILLIONS)
- TABLE 6 GLOBAL RA CONSULTATION & DIAGNOSIS MARKET, BY GEOGRAPHY 2007 -
2014 ($ MILLIONS)
- TABLE 7 GLOBAL RA THERAPY AND MONITORING MARKET, BY TECHNOLOGY 2007 - 2014
($ MILLIONS)
- TABLE 8 GLOBAL RA THERAPY AND MONITORING MARKET, BY GEOGRAPHY 2007 - 2014
($ MILLIONS)
- TABLE 9 GLOBAL RA DMARD AND BIOLOGIC DMARD THERAPY MARKET BY GEOGRAPHY
2007 - 2014 ($ MILLIONS)
- TABLE 10 GLOBAL RA BRIDGE THERAPY MARKET, BY GEOGRAPHY 2007 - 2014 ($
MILLIONS)
- TABLE 11 GLOBAL OTHER RA THERAPIES MARKET, BY GEOGRAPHY 2007 - 2014 ($
MILLIONS)
- TABLE 12 GLOBAL RA DRUGS MARKET, BY PRODUCTS 2007 - 2014 ($ MILLIONS)
- TABLE 13 GLOBAL RA DRUGS MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
- TABLE 14 GLOBAL RA NSAID MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
- TABLE 15 GLOBAL RA CORTICOSTERIODS MARKET, BY GEOGRAPHY 2007 - 2014 ($
MILLIONS)
- TABLE 16 GLOBAL OTHER RA DRUGS MARKET, BY GEOGRAPHY 2007 - 2014 ($
MILLIONS)
- TABLE 17 GLOBAL OTHER RA PRODUCTS AND SERVICES MARKET, BY GEOGRAPHY 2007 -
2014 ($ MILLIONS)
- TABLE 18 MAJOR COMPANIES AND THEIR RA PRODUCTS
- TABLE 19 MERGERS AND ACQUISITIONS IN THE RA MARKET
- TABLE 20 GLOBAL PSORIASIS MARKET, BY PRODUCTS 2007 - 2014 ($ MILLIONS)
- TABLE 21 GLOBAL PSORIASIS APPLICATIONS MARKET, BY GEOGRAPHY 2007 - 2014 ($
MILLIONS)
- TABLE 22 GLOBAL PSORIASIS CONSULTATION & DIAGNOSIS MARKET, BY GEOGRAPHY
2007 - 2014 ($ MILLIONS)
- TABLE 23 GLOBAL PSORIASIS THERAPY & MONITORING MARKET, BY TECHNOLOGY 2007
- 2014 ($ MILLIONS)
- TABLE 24 GLOBAL PSORIASIS THERAPY AND MONITORING MARKET, BY GEOGRAPHY 2007
- 2014 ($ MILLIONS)
- TABLE 25 GLOBAL PSORIASIS DRUGS MARKET, BY PRODUCTS 2007 - 2014 ($
MILLIONS)
- TABLE 26 GLOBAL PSORIASIS DRUGS MARKET, BY GEOGRAPHY 2007 - 2014 ($
MILLIONS)
- TABLE 27 GLOBAL ANTHRALIN PSORIASIS MARKET, BY GEOGRAPHY 2007 - 2014 ($
MILLIONS)
- TABLE 28 GLOBAL CALCIPOTRIENE PSORIASIS MARKET, BY GEOGRAPHY 2007 - 2014
($ MILLIONS)
- TABLE 29 GLOBAL NSAID PSORIASIS MARKET, BY GEOGRAPHY 2007 - 2014 ($
MILLIONS)
- TABLE 30 MAJOR COMPANIES AND THEIR PSORIASIS PRODUCTS
- TABLE 31 MERGERS & ACQUISITIONS IN THE PSORIASIS MARKET
- TABLE 32 GLOBAL LUPUS MARKET, BY APPLICATIONS 2007 - 2014 ($ MILLIONS)
- TABLE 33 GLOBAL LUPUS MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
- TABLE 34 GLOBAL OTHER SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY APPLICATIONS
2007 - 2014 ($ MILLIONS)
- TABLE 35 GLOBAL OTHER SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY GEOGRAPHY
2007 - 2014 ($ MILLIONS)
- TABLE 36 GLOBAL LOCALIZED DISEASES MARKET, BY APPLICATIONS 2007 - 2014 ($
MILLIONS)
- TABLE 37 GLOBAL LOCALIZED DISEASES MARKET, BY GEOGRAPHY 2007 - 2014 ($
MILLIONS)
- TABLE 38 GLOBAL MULTIPLE SCLEROSIS APPLICATIONS MARKET 2007 - 2014 ($
MILLIONS)
- TABLE 39 GLOBAL MULTIPLE SCLEROSIS APPLICATIONS MARKET, BY GEOGRAPHY 2007
- 2014 ($ MILLIONS)
- TABLE 40 GLOBAL MS DRUGS MARKET, BY PRODUCTS 2007 - 2014 ($ MILLIONS)
- TABLE 41 MAJOR COMPANIES AND THEIR MS PRODUCTS
- TABLE 42 MERGERS & ACQUISITIONS IN THE MS MARKET
- TABLE 43 GLOBAL INFLAMMATORY BOWEL DISEASE MARKET, BY APPLICATIONS 2007 -
2014 ($ MILLIONS)
- TABLE 44 GLOBAL INFLAMMATORY BOWEL DISEASE MARKET, BY GEOGRAPHY 2007 -
2014 ($ MILLIONS)
- TABLE 45 GLOBAL IBD CONSULTATION & DIAGNOSIS MARKET, BY GEOGRAPHY 2007 -
2014 ($ MILLIONS)
- TABLE 46 GLOBAL IBD THERAPY & MONITORING MARKET 2007 - 2014 ($ MILLIONS)
- TABLE 47 GLOBAL IBD DRUGS MARKET, BY PRODUCTS 2007 - 2014 ($ MILLIONS)
- TABLE 48 GLOBAL IBD DRUGS MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
- TABLE 49 MAJOR COMPANIES AND THEIR IBD PRODUCTS
- TABLE 50 MERGERS AND ACQUISITIONS IN IBD MARKET
- TABLE 51 GLOBAL TYPE I DIABETES MARKET, BY APPLICATIONS 2007 - 2014 ($
MILLIONS)
- TABLE 52 GLOBAL TYPE I DIABETES MARKET, BY GEOGRAPHY 2007 - 2014 ($
MILLIONS)
- TABLE 53 MAJOR COMPANIES AND THEIR TYPE I DIABETES PRODUCTS
- TABLE 54 MERGERS AND ACQUISITIONS IN THE TYPE I DIABETES MARKET
- TABLE 55 GLOBAL THYROID MARKET, BY APPLICATIONS 2007 - 2014 ($ MILLIONS)
- TABLE 56 GLOBAL THYROID MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
- TABLE 57 GLOBAL OTHER LOCALIZED AUTOIMMUNE DISEASES MARKET BY APPLICATIONS
2007 - 2014 ($ MILLIONS)
- TABLE 58 GLOBAL OTHER LOCALIZED AUTOIMMUNE DISEASES MARKET BY GEOGRAPHY
2007 - 2014 ($ MILLIONS)
- TABLE 59 GLOBAL AUTOIMMUNE TREATMENT MARKET, BY PRODUCT 2007 - 2014 ($
MILLIONS)
- TABLE 60 GLOBAL AUTOIMMUNE TREATMENT PRODUCTS MARKET BY GEOGRAPHY 2007 -
2014, ($ MILLIONS)
- TOTAL 61 GLOBAL AUTOIMMUNE DRUGS MARKET, BY PRODUCTS 2007 - 2014 ($
MILLIONS)
- TOTAL 62 GLOBAL AUTOIMMUNE DRUGS MARKET, BY GEOGRAPHY 2007 - 2014 ($
MILLIONS)
- TABLE 63 GLOBAL NSAID MARKET IN AUTOIMMUNE TREATMENT, BY GEOGRAPHY 2007 -
2014 ($ MILLIONS)
- TABLE 64 GLOBAL GLUCOCORTICOIDS MARKET IN AUTOIMMUNE TREATMENT BY
GEOGRAPHY 2007 - 2014 ($ MILLIONS)
- TABLE 65 GLOBAL METHOREXATE MARKET IN AUTOIMMUNE TREATMENT BY GEOGRAPHY
2007 - 2014 ($ MILLIONS)
- TABLE 66 GLOBAL HCQ MARKET IN AUTOIMMUNE TREATMENT, BY GEOGRAPHY 2007 -
2014 ($ MILLIONS)
- TABLE 67 GLOBAL HCQ MARKET IN AUTOIMMUNE TREATMENT, BY GEOGRAPHY 2007 -
2014 ($ MILLIONS)
- TABLE 68 GLOBAL CALCIPOTRIENE MARKET IN AUTOIMMUNE TREATMENT BY GEOGRAPHY
2007 - 2014 ($ MILLIONS)
- TABLE 69 GLOBAL CORTICOSTERIODS MARKET IN AUTOIMMUNE TREATMENT BY
GEOGRAPHY 2007 - 2014 ($ MILLIONS)
- TABLE 70 GLOBAL AMINOSALICYLATES/5-ASA/MESALAZINE MARKET IN AUTOIMMUNE
TREATMENT, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)TTABLE 71 GLOBAL AVONEX MARKET
IN AUTOIMMUNE TREATMENT, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
- TABLE 72 GLOBAL REBIF MARKET IN AUTOIMMUNE TREATMENT, BY GEOGRAPHY 2007 -
2014 ($ MILLIONS)
- TABLE 73 GLOBAL COPAXONE MARKET IN AUTOIMMUNE TREATMENT BY GEOGRAPHY 2007
- 2014 ($ MILLIONS)
- TABLE 74 GLOBAL BETASERON MARKET IN AUTOIMMUNE TREATMENT BY GEOGRAPHY 2007
- 2014 ($ MILLIONS)
- TABLE 75 GLOBAL OTHER AUTOIMMUNE DRUGS MARKET, BY GEOGRAPHY 2007 - 2014 ($
MILLIONS)
- TABLE 76 GLOBAL AUTOIMMUNE DIAGNOSTIC EQUIPMENT MARKET, BY PRODUCTS 2007 -
2014 ($ MILLIONS)
- TABLE 77 GLOBAL AUTOIMMUNE DIAGNOSTIC EQUIPMENT MARKET, BY GEOGRAPHY 2007
- 2014 ($ MILLIONS)
- TABLE 78 GLOBAL AUTOIMMUNE THERAPEUTIC AND MONITORING EQUIPMENT MARKET, BY
GEOGRAPHY 2007 - 2014 ($ MILLIONS)
- TABLE 79 GLOBAL OTHER AUTOIMMUNE PRODUCTS MARKET, BY GEOGRAPHY 2007 - 2014
($ MILLIONS)
- TABLE 80 GLOBAL SERVICES MARKET IN AUTOIMMUNE TREATMENT 2007 - 2014 ($
MILLIONS)
- TABLE 81 GLOBAL SERVICES MARKET IN AUTOIMMUNE TREATMENT BY GEOGRAPHY 2007
- 2014 ($ MILLIONS)
- TABLE 82 GLOBAL AUTOIMMUNE CONSULTATION & DIAGNOSIS MARKET BY GEOGRAPHY
2007 - 2014 ($ MILLIONS)
- TABLE 83 GLOBAL AUTOIMMUNE THERAPY & MONITORING MARKET BY GEOGRAPHY 2007 -
2014 ($ MILLIONS)
- TABLE 84 GLOBAL AUTOIMMUNE DRUG DEVELOPMENT MARKET, BY GEOGRAPHY 2007 -
2014 ($ MILLIONS)
- TABLE 85 GLOBAL AUTOIMMUNE TREATMENT TECHNOLOGY MARKET, BY PRODUCTS 2007 -
2014 ($ MILLIONS)
- TABLE 86 GLOBAL AUTOIMMUNE TREATMENT TECHNOLOGY MARKET BY GEOGRAPHY 2007 -
2014 ($ MILLIONS)
- TABLE 87 GLOBAL DMARD AND BIOLOGIC DMARD TECHNOLOGY MARKET BY GEOGRAPHY
2007 - 2014 ($ MILLIONS)
- TABLE 88 GLOBAL AUTOIMMUNE BRIDGE THERAPY MARKET, BY GEOGRAPHY 2007 - 2014
($ MILLIONS)
- TABLE 89 GLOBAL AUTOIMMUNE TOPICAL THERAPY MARKET, BY GEOGRAPHY 2007 -
2014 ($ MILLIONS)
- TABLE 90 GLOBAL AUTOIMMUNE PHOTOTHERAPY MARKET, BY GEOGRAPHY 2007 - 2014
($ MILLIONS)
- TABLE 91 GLOBAL AUTOIMMUNE HELMINTHIC THERAPY MARKET, BY GEOGRAPHY 2007 -
2014 ($ MILLIONS)
- TABLE 92 GLOBAL AUTOIMMUNE HEMATOPOIETIC STEM CELL TRANSPLANTATION MARKET,
BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
- TABLE 93 GLOBAL AUTOIMMUNE RECOMBINANT TECHNOLOGY MARKET BY GEOGRAPHY 2007
- 2014 ($ MILLIONS)
- TABLE 94 GLOBAL AUTOIMMUNE TREATMENT MARKET, BY GEOGRAPHY 2007 - 2014 ($
MILLIONS)
- TABLE 95 NORTH AMERICAN AUTOIMMUNE TREATMENT MARKET, BY APPLICATIONS 2007
- 2014 ($ MILLIONS)
- TABLE 96 EUROPEAN AUTOIMMUNE TREATMENT MARKET, BY APPLICATIONS 2007 - 2014
($ MILLIONS)
- TABLE 97 ASIA PACIFIC AUTOIMMUNE TREATMENT MARKET, BY APPLICATIONS 2007 -
2014 ($ MILLIONS)
- TABLE 98 ROW AUTOIMMUNE TREATMENT MARKET, BY APPLICATIONS 2007 - 2014 ($
MILLIONS)
- TABLE 99 U.S. PATENTS
- TABLE 100 EUROPE PATENT LIST
- TABLE 101 JAPAN PATENT TABLE
List of Figures
- FIGURE 1 FACTORS CAUSING AUTOIMMUNE DISEASES
- FIGURE 2 CHRONOLOGY OF EVOLUTION OF THERAPIES AND DRUGS
- FIGURE 3 FOCUS LEVELS FOR GROWTH IN AUTOIMMUNE TREATMENT
- FIGURE 4 GLOBAL AUTOIMMUNE MARKET, BY GEOGRAPHY FOR 2009
- FIGURE 5 CLASSIFICATION OF AUTOIMMUNE DISEASES BY APPLICATIONS
- FIGURE 6 POSITIONING APPLICATIONS IN THE MARKET FOR AUTOIMMUNE TREATMENT
- FIGURE 7 MARKET SHARE OF AUTOIMMUNE DRUGS IN 2009
- FIGURE 8 COMPARISON OF FOUR MAJOR DRUGS IN MS APPLICATIONS
- FIGURE 9 EUROPEAN MARKETS FOR AUTOIMMUNE TREATMENT, IN 2009 (%)
- FIGURE 10 NUMBER OF PATENTS ISSUED (JANUARY 2004 - JUNE 2009)
- FIGURE 11 NUMBER OF PATENTS ISSUED BY GEOGRAPHY (JANUARY 2004 - JUNE 2009)
- FIGURE 12 GEOGRAPHICAL ANALYSIS (JANUARY 2004 - JUNE 2009)
|
Related Report
|